nitazoxanid
ntz
thiazolid
agent
activ
anaerob
bacteria
protozoa
virus
tabl
origin
develop
treatment
intestin
protozoan
infect
antivir
properti
ntz
discov
cours
develop
treat
cryptosporidiosi
patient
acquir
immun
defici
syndrom
recent
random
clinic
trial
demonstr
effect
ntz
treat
rotaviru
may
effect
hepat
viru
effect
suggest
drug
deriv
may
candid
test
neurotrop
virus
deliv
across
barrier
seri
pyrazinecarboxamid
deriv
favipiravir
antivir
drug
target
rna
virus
influenza
viru
arenavirus
bunyavirus
west
nile
viru
wnv
yellow
fever
viru
diseas
viru
compound
inhibit
host
dna
rna
synthesi
compound
effect
protect
anim
even
treatment
initi
viru
inocul
importantli
impart
benefici
antivir
effect
without
signific
toxic
two
structur
unrel
compound
activ
virtual
envelop
rna
dna
uniqu
enzym
regulatori
protein
encod
genom
specif
neurotrop
virus
excel
target
specif
antivir
therapi
tabl
approach
work
well
exemplifi
drug
target
dna
polymeras
herp
simplex
viru
hsv
revers
transcriptas
integras
proteas
hiv
understand
step
viral
replic
cycl
allow
similar
approach
neurotrop
virus
exampl
regard
flavivirus
envelop
glycoprotein
sever
enzym
proteas
helicas
methyltransferas
rna
polymeras
potenti
drug
similarli
target
viral
proteas
success
drug
boceprevir
telaprevir
develop
hepat
c
becom
clear
current
antiretrovir
therapi
art
abl
elimin
neurocognit
despit
intensif
art
cn
dysfunct
persist
mani
underli
reason
failur
persist
immun
activ
unclear
howev
sever
factor
consid
includ
microbi
transloc
persist
product
earli
viral
product
tat
current
avail
drug
impact
tat
transcript
provir
dna
novel
approach
treatment
hiv
infect
includ
target
host
protein
involv
viral
assembl
howev
drug
target
tat
need
major
shift
hiv
drug
develop
occur
recent
realiz
isol
case
hiv
could
elimin
reservoir
allow
true
cure
sever
clinic
trial
underway
use
varieti
approach
develop
lymphocyt
activ
latent
reservoir
immun
system
presenc
art
hope
cytotox
lymphocyt
would
elimin
viral
reservoir
thu
far
approach
fail
produc
cure
concern
rais
activ
hiv
although
acyclovir
remain
wide
use
drug
hsv
recent
year
sever
drug
seen
clinic
use
includ
valaciclovir
valganciclovir
famciclovir
foscarnet
drug
clinic
trial
includ
prodrug
cidofovir
inhibitor
valin
ester
cf
terminas
inhibitor
given
oral
antivir
activ
dna
virus
howev
toxic
cn
deliveri
develop
viral
resist
potenti
limit
factor
gener
use
newer
agent
variat
theme
target
therapi
use
antisens
oligonucleotid
analog
engin
inhibit
translat
viral
protein
specif
bind
rna
sequenc
viral
genom
particular
subtyp
antisens
molecul
dna
ribos
ring
replac
morpholin
ring
phosphodiest
linkag
replac
phosphorodiamid
phosphorodiamid
morpholino
oligom
pmo
pmo
success
inhibit
wide
varieti
neurotrop
virus
includ
japanes
enceph
viru
jev
cell
cultur
significantli
influenza
alphaviru
lymphocyt
choriomening
mice
relat
strategi
use
rna
interfer
rna
also
proven
success
anim
model
develop
measl
well
potenti
treat
subacut
scleros
panenceph
caus
persist
measl
success
preclin
studi
led
trial
avi
biopharma
sarepta
therapeut
interfer
wnv
mrna
translat
use
pmo
human
trial
relat
studi
suggest
pmo
test
cross
barrier
safe
administ
although
efficaci
data
avail
rna
dna
produc
viral
replic
recogn
host
pathogen
recognit
receptor
includ
famili
receptor
tlr
receptor
rlr
signal
tlr
rlr
occur
via
intermediari
protein
eg
interferon
regulatori
factor
induc
new
gene
transcript
activ
antivir
program
best
exemplifi
type
interferon
respons
gene
product
implic
pathophysiolog
viral
infect
exampl
sever
studi
human
anim
link
aspect
wnv
infect
acquisit
symptomat
vs
nonsymptomat
diseas
neuroinvas
diseas
gene
includ
member
oligoadenyl
synthetas
oa
interferon
regulatori
famili
gene
also
link
resist
flaviviru
infect
suscept
develop
wnv
enceph
cytokin
tumor
necrosi
also
play
role
innat
immun
respons
viral
infect
exampl
wnv
infect
although
suggest
elev
level
may
increas
risk
develop
west
nile
neuroinvas
diseas
impair
endotheli
cell
integr
facilit
viral
entri
across
barrier
mice
lack
tnf
receptor
treat
neutral
monoclon
antibodi
mab
show
increas
mortal
wnv
challeng
increas
viral
load
suggest
role
may
complex
aspect
facilit
neuroinvas
other
facilit
antivir
role
includ
accumul
cell
interestingli
polymorph
promot
region
associ
alter
transcript
plasma
level
link
risk
develop
enceph
oppos
milder
febril
ill
follow
jev
infect
exampl
patient
allel
odd
ratio
develop
jev
fever
oppos
enceph
wherea
allel
risk
multipl
studi
mice
indic
tlr
rlr
recogn
nucleic
acid
gener
viral
replic
subsequ
lead
activ
type
interferon
ifn
respons
transcript
respons
mediat
ifn
regulatori
factor
mice
lack
interferon
rlr
show
enhanc
sever
wnv
infect
enhanc
viral
replic
compar
counterpart
case
defici
least
enhanc
suscept
like
due
failur
leukocyt
macrophag
home
cell
infiltr
infect
target
organ
similarli
least
part
effect
delet
enhanc
wnv
mortal
spread
link
role
induc
cytokin
turn
facilit
recruit
macrophag
cell
major
case
hsve
sporad
natur
lack
defin
immunolog
risk
factor
howev
children
inborn
error
defect
result
abnorm
signal
sever
antivir
tlr
includ
eg
defici
suscept
hsve
common
compon
associ
defect
impair
interferon
signal
mani
case
cell
deriv
affect
individu
show
enhanc
hsv
replic
cytopath
phenotyp
rescu
treatment
human
genet
data
consist
experiment
studi
show
mice
lack
ifn
receptor
enhanc
growth
hsv
cn
increas
mortal
intracerebr
viral
challeng
studi
indic
effect
type
ifn
respons
critic
murin
surviv
murin
studi
also
point
import
tlr
control
hsv
infect
exampl
mice
lack
show
enhanc
mortal
hsv
import
innat
immun
natur
control
cn
viral
infect
suggest
augment
pathway
could
provid
novel
strategi
antivir
therapi
experiment
evid
avail
support
approach
exampl
mice
treat
combin
acyclovir
show
reduct
mortal
hsv
challeng
compar
mice
treat
acyclovir
agonist
also
studi
murin
model
hsve
agonist
typic
cpg
oligodeoxynucleotid
activ
product
studi
mous
model
hsve
intranas
administr
agonist
polyinosin
polycytidyl
acid
intranas
hsv
challeng
reduc
sever
diseas
howev
administr
infect
alreadi
establish
increas
mortal
diseas
similar
experiment
model
agonist
pretreat
increas
surviv
interestingli
antagonist
also
modest
effect
improv
surviv
given
either
follow
viral
challeng
result
suggest
case
cytokin
respons
may
reduc
risk
infect
play
detriment
role
establish
infect
suggest
potenti
complex
target
pathway
antivir
therapi
agonist
rintatolimod
ampligen
also
evalu
murin
model
venezuelan
equin
enceph
viru
cn
infect
intranas
intraperiton
administr
ampligen
hour
relat
intranas
venezuelan
equin
enceph
viru
challeng
prevent
neuroinvas
develop
symptomat
diseas
even
ampligen
administ
hour
treat
mice
show
decreas
cn
viral
invas
minim
anoth
strategi
reduc
product
proinflammatori
cytokin
may
detriment
role
infect
involv
use
tetracyclin
class
antibiot
includ
minocyclin
doxycyclin
agent
may
exert
neuroprotect
effect
reduc
microgli
activ
subsequ
product
proinflammatori
cytokin
benefici
effect
drug
diseas
sever
cn
injuri
report
murin
model
alphaviru
sindbi
flaviviru
jev
reoviru
macaqu
model
siv
one
notabl
except
mostli
posit
result
rabi
enceph
therapi
actual
enhanc
diseas
experiment
studi
suggest
manipul
host
innat
immun
respons
might
produc
novel
strategi
treat
cn
viral
infect
one
obviou
approach
tri
treatment
sever
human
neurotrop
viral
infect
involv
direct
administr
ifn
prepar
nonrandom
trial
involv
saint
loui
enceph
patient
receiv
million
unit
intraven
subcutan
hour
daili
day
seem
less
persist
quadriparesi
quadriplegia
respiratori
insuffici
untreat
isol
case
report
ifn
therapi
wnv
shown
exampl
appar
random
trial
children
vietnam
jev
million
intramuscularli
day
effect
mortal
incid
sever
furthermor
unlik
benefit
progress
multifoc
leukoencephalopathi
due
jcv
case
hsve
almost
data
avail
small
studi
children
acut
focal
enceph
receiv
either
acyclovir
alon
acyclovir
plu
recombin
appreci
differ
outcom
treatment
licens
inhibitor
util
treatment
psoriasi
inflammatori
bowel
diseas
rheumatoid
arthriti
adalimumab
etanercept
infliximab
golimumab
certolizumab
data
concern
possibl
util
cn
viral
infect
tlr
agonist
includ
ampligen
human
clinic
trial
set
includ
hiv
infect
eg
chronic
fatigu
syndrom
yet
evalu
cn
infect
potenti
cautionari
note
use
antagonist
antivir
therapi
least
case
hsv
enceph
report
patient
treat
infliximab
n
adalimumab
n
rheumatolog
disord
includ
psoriat
arthriti
rheumatoid
arthriti
inflammatori
similarli
treatment
inhibitor
may
increas
risk
herp
zoster
review
german
registri
patient
treat
biolog
found
case
zoster
associ
treatment
antibodi
adalimumab
infliximab
antagonist
etanercept
estim
hazard
ratio
hr
correct
epidemiolog
factor
confid
interv
ci
antibodi
nonsignific
hr
ci
etanercept
recent
us
studi
fail
find
increas
risk
herp
zoster
rheumatoid
arthriti
patient
treat
area
remain
unsettl
studi
least
rais
cautionari
possibl
herpesvirus
may
play
role
control
reactiv
latenc
latent
state
seen
arbovir
infect
potenti
risk
benefit
inhibit
infect
may
differ
seen
herp
viral
infect
use
tnf
blocker
may
also
increas
risk
reactiv
mycobacteri
may
limit
use
popul
mycobacteri
infect
endem
although
report
pml
patient
receiv
therapi
includ
patient
report
date
diseas
therapi
associ
risk
pml
recent
review
us
food
drug
administr
advers
event
report
system
databas
identifi
case
patient
rheumat
diseas
conclud
causal
relationship
pml
therapi
cytokin
interleukin
il
also
use
simul
immun
system
enhanc
antivir
respons
howev
fail
show
clinic
benefit
larg
clinic
supplement
treatment
actual
enhanc
hiv
persist
patient
receiv
antiretrovir
cytokin
therapi
yet
specif
appli
patient
cn
viral
infect
treatment
tetracyclin
class
antibiot
may
effect
proinflammatori
cytokin
product
clinic
studi
infect
flaviviru
dengu
doxycyclin
treatment
load
everi
hour
day
shown
reduc
serum
level
varieti
proinflammatori
cytokin
tnf
whose
express
link
increasingli
sever
diseas
day
compar
tradit
vaccin
use
mean
boost
immun
respons
viral
pathogen
approach
success
varicella
zoster
viru
prevent
zoster
similar
approach
consid
jcv
howev
approach
may
limit
patient
signific
immun
suppress
henc
approach
consid
passiv
transfer
cytotox
cell
ctl
protect
studi
suggest
possibl
transfer
immun
cell
may
use
treatment
human
viral
cn
infect
proof
principl
human
cn
diseas
come
treatment
patient
pml
follow
hematopoiet
stem
cell
transplant
immunosuppress
graft
versu
host
peripher
blood
mononuclear
cell
pbmc
obtain
stem
cell
donor
jcv
ctl
gener
vitro
stimul
cell
peptid
deriv
jcv
month
patient
receiv
infus
develop
measur
ctl
activ
viral
protein
detect
preinfus
show
remark
sign
clinic
ambul
motor
function
cognit
magnet
reson
imag
improv
viru
clear
cerebrospin
fluid
csf
patient
also
receiv
antivir
therapi
alter
immunosuppress
therapi
possibl
unequivoc
attribut
respons
immunotherapi
nonetheless
case
show
potenti
feasibl
gener
infus
ctl
impart
measur
antivir
ctl
activ
recipi
done
safe
number
studi
passiv
transfer
cytomegaloviru
cmv
ctl
report
techniqu
matur
effort
focus
develop
rapid
cultur
vitro
stimul
viral
peptid
follow
select
purifi
cell
transfer
back
host
accomplish
transfer
typic
result
develop
measur
ctl
activ
recipi
often
absent
pretransf
cell
transfer
use
success
patient
diseas
refractori
antivir
model
studi
involv
patient
cmv
enceph
respond
clinic
clearanc
viru
blood
andor
csf
ctl
donor
pbmc
also
isol
bind
receptor
specif
construct
multim
contain
target
interest
eg
cmv
ebv
nuclear
antigen
peptid
coupl
appropri
major
histocompat
complex
human
leukocyt
perhap
compon
host
defens
viral
infect
gener
antibodi
respons
advent
mab
technolog
becam
possibl
map
protect
epitop
specif
viral
protein
review
griffin
et
shown
virus
passiv
transfer
mab
direct
protein
could
clear
viru
viral
nucleic
acid
cn
neuron
even
mice
defici
cellular
clearanc
could
occur
infect
cn
human
form
antibodi
develop
similar
protect
capac
experiment
model
enceph
involv
arbovirus
includ
venezuelan
equin
enceph
jev
wnv
well
postexposur
prophylaxi
pep
human
mab
also
test
anim
model
neurotrop
virus
includ
enteroviru
model
infect
influenza
virus
includ
pandem
studi
use
human
mab
treatment
herpesviru
infect
limit
although
one
report
use
human
mab
mous
model
hsv
ocular
anim
significantli
reduc
ocular
diseas
human
mab
direct
epitop
wnv
envelop
glycoprotein
protect
mous
hamster
model
wnv
enceph
test
safeti
human
antibodi
administ
normal
volunt
dose
intraven
infus
well
toler
pharmacokinet
studi
indic
day
level
achiev
substanti
exceed
requir
protect
hamster
anoth
promis
area
use
human
mab
pep
rabi
viru
infect
estim
million
million
peopl
worldwid
receiv
rabi
pep
everi
year
minimum
rabi
death
current
regimen
reli
use
either
human
equin
rabi
immunoglobulin
coadminist
rabi
vaccin
phase
trial
indic
cocktail
human
viru
mab
manufactur
crucel
holland
leiden
netherland
administ
intramuscularli
safe
phase
human
trial
interfer
develop
subsequ
rabi
two
phase
ii
trial
complet
children
adolesc
philippin
adult
unit
state
follow
third
trial
adult
india
complet
late
data
avail
suggest
human
mab
viabl
altern
polyclon
antirabi
immunoglobulin
pep
new
technolog
approach
may
enhanc
util
human
mab
approach
cn
viral
infect
almost
trial
human
mab
util
passiv
transfer
techniqu
antibodi
directli
administ
either
intraven
eg
wnv
intramuscularli
rabi
novel
strategi
refer
vector
immunoprophylaxi
util
gene
transfer
express
high
level
antibodi
prolong
period
human
mab
transfer
convent
passiv
method
protect
mice
human
immun
system
hiv
human
neutral
antibodi
also
protect
express
singl
intramuscular
inject
mice
use
system
antibodi
detect
within
week
inject
peak
week
persist
week
type
model
may
promis
approach
avoid
repeat
administr
antibodi
situat
chronic
diseas
continu
risk
exposur
treatment
must
ideal
maintain
period
exceed
individu
antibodi
administr
note
typic
target
human
antivir
antibodi
specif
viral
protein
use
cocktail
pool
sever
antibodi
may
enhanc
efficaci
reduc
likelihood
select
viral
escap
mutant
anoth
strategi
use
antibodi
target
key
host
cell
compon
involv
viral
bind
entri
rather
viral
protein
per
se
strategi
success
util
hiv
infect
differ
human
mab
pro
direct
domain
extracellular
loop
hiv
receptor
shown
safe
well
toler
reduc
plasma
hiv
viral
load
phase
iii
phase
trial
also
shown
similar
safeti
efficaci
human
mab
ibalizumab
direct
new
therapi
viral
cn
infect
develop
base
understand
target
specif
step
viru
replic
cycl
util
knowledg
gain
increasingli
sophist
understand
host
antivir
immun
respons
includ
innat
humor
immun
host
potenti
novel
approach
cn
antivir
therapi
avail
experiment
preclin
level
rariti
mani
cn
infect
unpredict
especi
diseas
pose
formid
challeng
design
clinic
trial
equal
daunt
challeng
establish
econom
viabl
pathway
new
drug
develop
nonetheless
econom
public
health
burden
exist
emerg
cn
viral
threat
make
progress
identifi
specif
antivir
therapi
imper
klt
board
membership
dsmb
lpath
consult
pml
consortium
genentech
roch
johnson
johnson
pfizer
janssen
pharmaceut
biogen
expert
testimoni
bassett
law
firm
royalti
elsevi
travel
expens
american
neurolog
associ
editori
board
servic
neurolog
today
aan
editori
board
archiv
neurolog
